Novamigra Therapeutics Secures ~€3 Million Funding to Advance First-in-Human Study of Migraine Prophylaxis Asset VRG-145
Novamigra Therapeutics secures ~€3 million funding to advance first-in-human Phase 1 study of its migraine prophylaxis asset VRG-145 BUDAPEST, HUNGARY, January 9, 2026 /EINPresswire.com/ -- Novamigra Therapeutics, a spin-out venture of VRG …